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Abstract
Background: Colorectal cancer is one of the most common cancers in the world, killing nearly 50% of patients
afflicted. Though progress is being made within surgery and other complementary treatments, there is still need
for new and more effective treatments. Oncolytic virotherapy, meaning that a cancer is cured by viral infection, is a
promising field for finding new and improved treatments. We have investigated the oncolytic potential of several
low-pathogenic echoviruses with rare clinical occurrence. Echoviruses are members of the enterovirus genus within
the family Picornaviridae.
Methods: Six colon cancer cell lines (CaCo-2, HT29, LoVo, SW480, SW620 and T84) were infected by the human
enterovirus B species echovirus 12, 15, 17, 26 and 29, and cytopathic effects as well as viral replication efficacy
were investigated. Infectivity was also tested in spheroids grown from HT29 cells.
Results: Echovirus 12, 17, 26 and 29 replicated efficiently in almost all cell lines and were considered highly
cytolytic. The infectivity of these four viruses was further evaluated in artificial tumors (spheroids), where it was
found that echovirus 12, 17 and 26 easily infected the spheroids.
Conclusions: We have found that echovirus 12, 17 and 26 have potential as oncolytic agents against colon cancer,
by comparing the cytolytic capacity of five low-pathogenic echoviruses in six colon cancer cell lines and in artificial
tumors.
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Background
Colorectral cancer is the second and third most commonly
diagnosed cancer in the world for women and men
respectively. Nearly 50% of those diagnosed with colorectal
cancer are killed from it, and in 2008 there were more
than 1.2 million new cases estimated of colorectal cancer
[1]. Presently the most common treatment of colorectal
cancer is surgery, where chemotherapy and radiation may
be used as adjuvants [2]. Though progress is made within
these therapies, the nearly 50% mortality rate indicates the
necessity of new and improved treatments of colorectal
cancer.
Viral oncolysis offers a new promising field of cancer
treatments. The research area has broadened to include
several different mechanisms of antitumoral efficacy; for
instance direct tumor cell lysis due to viral replication or
viral cytotoxic proteins and transgene expression
(reviewed in [3,4]). Many of the oncolytic viruses that
have been tested in clinical trials are genetically modified,
in particular adenoviruses and herpes simplex virus
(reviewed in [5-7]). Several other viruses, including pox-
viruses, reovirus and Newcastle disease virus have also
shown promising antitumor effects in various human
malignancies (reviewed in [4,8-10]).
Echoviruses (E) are serotypes belonging in the Human
Enterovirus B (HEV-B) species within the enterovirus (EV)
genus of Picornaviridae. Picornaviruses are small (dia-
meter about 30 nm), naked, icosahedrically shaped viruses
with an RNA genome of about 7.2 to 8.5 kb in length with
positive polarity [11,12]. Within the EV genus both E1 and
coxsackievirus A21 have been shown to be oncolytic in
several human cancers, including malignant melanoma
and ovarian cancer [13-18]. In addition, it has been
reported that bovine EV shows oncolytic characteristics
[19], and attenuated, recombinant poliovirus strains have
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Recently another picornavirus, Seneca valley virus, has
also emerged as an oncolytic virotherapy candidate
[23,24].
The HEV-B species contains many viruses with rare
clinical occurrence and low pathogenicity, making them
potentially suitable for oncolytic virotherapy if they show
oncolytic characteristics. The serotypes within the HEV-
B species that were chosen to be included in this study of
cytolytic capacity were E12, E15, E17, E26, and E29.
These viruses were all isolated in the 1950’s from healthy
persons [25-30] and chosen on the basis of their low
pathogenicity [31-34]. In this paper, the cytolytic effects
of these five serotypes were investigated in six cell lines
derived from cancers of the human colon. Colorectal
cancer was chosen due to the fecal-oral route of infectiv-
ity of enteroviruses [12] and its position as one of the
most common forms of cancer with a mortality rate of
nearly 50% [1]. Those serotypes that generated the most
efficient cythopathic effect (CPE) and highest amount of
viral progeny, in cell lines grown as monolayers, were
also tested for infectivity in spheroids (reviewed in [35]).
Infection of spheroids enables investigation of the cap-
ability to spread within an artificial tumor of three-
dimensional shape.
Materials and methods
Cell lines and viruses
The colon cancer cell lines HT29, SW480, SW620, LoVo,
and T84 were purchased from European Collection of
Cell Cultures (ECACC, UK) and CaCo-2 was generously
provided by C. Gustafson-Svärd (Linnaeus University,
Kalmar, Sweden). A local variant of green monkey kidney
(GMK) cells and Chinese hamster ovary (CHO) cells,
kindly provided by H.-C. Selinka (University of Tübingen,
Tübingen, Germany), were used as positive and negative
control for infectivity studies. SW480, SW620, CaCo-2,
GMK and CHO were cultured in Dulbeccos modified
Eagle’sm e d i u m( D M E M ) ,H T 2 9w a sc u l t u r e di n
McCoy’s 5A medium and LoVo and T84 were cultured
in Ham’s F12 medium. Medias were supplemented with
100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM
L-glutamine and 10% newborn calf serum (NCS). 5%
NCS were used in GMK and CHO media. CaCo-2 media
was additionally supplemented with 0.1 mM non-essen-
tial amino acids (NEAA). Cell lines were grown in 37°C
and 7.5% CO2 (HT29, SW480, SW620, GMK and CHO)
or 5.0% CO2 (CaCo-2, LoVo and T84). E15 Charleston
was purchased from American Type Culture Collection
(ATCC, VR-45), E12 Travis,E 1 7CHHE-29 and E26 Cor-
onel were generously provided by J.-Å. Liljeqvist, (Univer-
sity of Gothenburg, Gothenburg, Sweden) and E29 JV-10,
was kindly provided by M. Roivainen (National Institute
for Health and Welfare, Helsinki, Finland).
Viral serotype confirmation
Viral serotypes were confirmed genetically by RNA extrac-
tion using QIAamp viral RNA MiniSpinKit (Qiagen)
according to manufacturer’s manual. RNAs were reverse
transcribed (RT) by SuperScript III RT enzyme (Invitro-
gen) using a primer 5’-ATAAGAATGCGGCCGCT27-3’ at
50°C for 60 minutes and the enzyme was inactivated at
70°C. cDNAs were amplified by PCR using PuReTaq
Ready-To-Go PCR Beads (GE Healthcare) and primers
matching the flanking sequences of the VP1 region of
each viral strain. Nucleotide sequences were determined
using the ABI Prism BigDye terminator cycle sequencing
reaction kit (Applied Biosystems) and a 3130 Genetic Ana-
lyzer (Applied Biosystems). Sequencher version 4.5 (Gene
Codes Corporation) was used for editing of sequences.
Obtained viral sequences were determined by strain using
basic local alignment search tool (BLAST, National Center
for Biotechnology Information, NCBI). Prior to virus infec-
tivity assays all viruses were propagated and titrated in
GMK cells using the endpoint titration method of Sper-
man and Kärber [36].
Virus infectivity assay
Cells were grown in 6 well plates (HT29, SW480, SW620,
LoVo, T84, GMK and CHO) or in T25 bottles (CaCo-2)
to a confluence of 50-85%. The cells were washed in
phosphate buffered saline (PBS) and serum free medias
were added to cells: McCoy’s 5A to HT29, DMEM to
SW480, SW620, GMK and CHO and OptiMEM to T84,
LoVo and CaCo-2. CaCo-2 media was additionally sup-
plemented with 0.1 mM NEAA. Cells were infected with
viruses at a multiplicity of infection (MOI) of 1 in double
samples and incubated in room temperature for 60 min-
utes. The virus containing medias were exchanged for
new serum free equivalents, and one sample per cell line
and virus (E12, E15, E17, E26 or E29) was frozen while
the other remaining sample was incubated in 37°C until
complete CPE was visible, or for a maximum of seven
days. At the time of complete CPE, or after seven days,
cells were photographed using microscopy. All infection
assays were performed three times. After freezing and
thawing three times, all infection samples were titrated in
GMK cells.
Culture of spheroids and spheroid infectivity assay
HT29 spheroids were cultured in 24 well plates by inocu-
lating 1 000 cells per well, coated with 1% agarose in PBS,
in 1 ml McCoy’s 5A media supplemented with 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine
and 10% NCS. Single spheroids were allowed to form for
seven days in 37°C, 7.5% CO2.1 0
5 tissue culture infectious
dose 50% (TCID50) of each virus (E12, E17, E26 or E29)
were added to spheroids, and the infections were followed
for nine days. Infections were repeated on at least two
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in spheroids 14 to 18 times in total.
Viability confirmation of spheroids
HT29 spheroids, uninfected or infected by E29, were
washed separately three times in PBS to remove any sin-
gle cells or unbound viral particles and dispersed in
0.25% trypsin-EDTA solution. McCoy’s media supple-
mented with 100 U/ml penicillin, 0.1 mg/ml streptomy-
cin, 2 mM L-glutamine and 10% NCS was added. Cells
were diluted 1:2 in trypan blue solution, incubated for
10 minutes and examined in a Bürker chamber using
microscopy. Trypsinated cells from uninfected spheroids
were also allowed to proliferate in 6 well plates for two
days.
Results
Viral infectivity in colon cancer cell lines
To investigate the oncolytic potential of E12, E15, E17,
E26 and E29 against colorectal cancer initially, the cyto-
lytic replication in six colon cancer cell lines (Table 1)
was analyzed. Viral ability to cause CPE was investigated
(Table 2, Additional file 1) as well as increase in viral
titers during infection (Figure 1). GMK and CHO cells
were used as positive and negative infectious control
respectively (data not shown).
E12 was able to infect all colon cancer cell lines generat-
ing an increase in titer of about four logs, 10
3-4 to 10
7-8
TCID50/ml, in HT29, SW480, SW620 and CaCo-2
(Figure 1). The mean titer of E12 attached to LoVo
(10
2.89 TCID50/ml) and that of the viral progeny (10
3.94
TCID50/ml) indicate that the virus replicated in the cell
line, but no CPE was observed after seven days (Table 2,
Figure 1). In all other colon cancer cell lines complete
CPE was observed within two to three days, although the
viral mean titer decreased during the infection in T84.
E15 generated complete CPE in CaCo-2, HT29,
SW620 and T84 within two to seven days, but the mean
titers of viral progeny, compared to titers of initially
attached virus particles, were markedly higher only in
t h ec a s eo fH T 2 9a n dC a C o - 2( T a b l e2 ,F i g u r e1 ) .I n
T84, complete CPE was observed after two days, but no
viral progeny was measured by titration. No infection
was indicated in LoVo or SW480.
In the case of E17, the virus bound to all colon cancer
cell lines (Figure 1). In all cell lines except LoVo, complete
CPE was observed within one to seven days (Table 2).
CPE was also supported by an increase in mean titer
between bound virus and viral progeny of about two to
four logs in all cases where CPE was observed, except in
SW680, where the mean titer increased with less than one
log (Figure 1). Although E17 attached to the cellular sur-
face of LoVo (mean initial titer of attached viral particles;
10
3.95 TCID50/ml), no CPE was observed, nor was any
viral progeny detected by endpoint titration after seven
days.
E26 was able to cause complete CPE in CaCo-2,
H T 2 9 ,S W 6 2 0a n dT 8 4w i t h i nt w ot os e v e nd a y s .I n
SW480 only partial CPE was observed after seven days,
while no CPE was observed in LoVo after the same time
(Table 2). During infection viral mean titers increased
about five to seven logs in all infected colon cancer cell
lines except LoVo, where no viral progeny was indicated
by titration (Figure 1). Mean titers of viral progeny
reached about 10
5 to 10
8 TCID50/ml in all cell lines
except LoVo.
E29 caused complete CPE in two to seven days in
CaCo-2, HT29, SW480 and SW620, generating viral
mean titers of about 10
5 to 10
8 TCID50/ml, even though
Table 1 Cell lines derived from human colorectal cancers used in this study
Cell line Colorectal disease Tumor stage Primary tumor/Derived from metastatic site
CaCo-2 adenocarcinoma - Primary tumor
HT29 adenocarcinoma - Primary tumor
LoVo adenocarcinoma Dukes’ type C Left supraclavicular region
SW480 adenocarcinoma Dukes’ type B Primary tumor
SW620 adenocarcinoma Dukes’ type C Lymph node
T84 carcinoma - Lung
Data are adapted from the American Type Culture Collection (ATCC) catalogue.
-: Tumor stage is not specified.
Table 2 Cytopathic effect (CPE) caused by echoviral
infection in colon cancer cell lines
Virus Colon cancer cell line
CaCo-2 HT29 LoVo SW480 SW620 T84
E12 + (3) + (3) - (7) + (2) + (3) + (3)
E15 + (7) + (3) - (7) - (7) + (5) + (2)
E17 + (2) + (1) - (7) + (6) + (7) + (1)
E26 + (5) + (2) - (7) +/- (7) + (7) + (2)
E29 + (3) + (2) - (7) + (5) + (7) - (7)
Infections were followed until complete CPE was observed or seven days
maximum. Days post infection until complete or partial CPE are indicated
within parenthesis. Pictures of infected cells are available in Additional file 1.
+: complete CPE
-: no CPE
+/-: partial CPE
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in very low amounts (Table 2, Figure 1). E29 also caused
an infection in T84, generating a viral progeny mean
titer of 10
4.88 TCID50/ml, but no CPE was observed.
LoVo was uninfected by E29.
To summarize these results, E12, E17, E26 and E29 are
able to proliferate efficiently and cause cytolytic infection
in most of the cell lines included in this study. E15 was
excluded at this stage, due to its relatively poor ability to
proliferate and cause CPE in the colon cancer cell lines
investigated.
Viral infectivity in HT29 spheroids
Three-dimensionally in vitro growing cells, referred to as
spheroids (reviewed in [35]), allow viruses to infect cells in
a more tumor-like environment rather than the infection
of a bi-dimensional monolayer. Spheroids of the human
colon cancer cell line HT29 were infected by E12, E17,
E26 and E29. The results show that E12, E17 and E26
destroyed the spheroids within five to nine days (Figure 2).
E29 was not able to destroy HT29 spheroids within nine
days. Viability of spheroids, both uninfected and infected
by E29, was confirmed by individualization of spheroid
cells using trypsin treatment, followed by trypan blue
staining (data not shown). Viability of uninfected spher-
oids was additionally confirmed by allowing the individua-
lized cells to proliferate as monolayers (data not shown).
Discussion
Though improvements are being made, patient prognosis
of colorectal cancer is still poor [1]. Presently surgical
restriction, chemotherapy and radiation are the most
common therapeutic approaches [2]. A promising new
field in the battle against cancer is oncolytic virotherapy,
which is undergoing extensive investigation. In this
study, we investigated the cytolytic capacity of low- or
apathogenic echoviruses within the HEV-B species in
colon cancer cell lines, grown both as monolayers and as
three-dimensional spheroids.
Wild type enteroviruses may be suitable as oncolytic
viruses for several reasons. (i) Enteroviruses have been
studied epidemiologically for over 50 years and many of
these viruses are strictly human pathogens causing low-
or even asymptomatic infections [12]. It is therefore well
known that there are viruses within this genus with a
relatively safe profile from a pathological point of view.
This is a favorable characteristic of an oncolytic virus. It
should be mentioned though, that low-pathogenic enter-
oviruses might be associated with more severe symptoms
occasionally [37,38]. (ii) Wild type enteroviruses with low
pathogenicity can be oncolytic without genetic engineer-
ing [16,17]. This eliminates the risks of potential rever-
sion to virulent phenotypes of attenuated oncolytic
viruses or loss of malignant tissue specificity as a conse-
quence of genetic engineering. (iii) There are antipicor-
navirus drugs such as Pleconaril. This drug has been
used successfully on a compassionate-release basis
[39,40]. (iv) Low-pathogenic enteroviruses may be rare in
the human population [16,31]. This decreases the risk of
patients having an acquired immunity towards the virus
prior to deliberate infection for oncolytic virotherapy
purposes. (v) Possibly several different serotypes with
Figure 1 Viral infections of colon cancer cell lines. Six colon cancer cell lines: CaCo-2, HT29, LoVo, SW480, SW620 and T84, were infected by
either echovirus 12, 15, 17, 26 or 29 in double triplicates. Infections were frozen directly after infection (bound viruses) or incubated until
complete CPE was reached, or maximum seven days (viral progeny). All infections were titrated in green monkey kidney cells after having been
frozen and thawed three times. Results are presented as mean TCID50/ml values ± standard deviation.
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be identified. Serotypes could then be altered successively
if administrating more than one oncolytic virus to a
patient. This would provide a strategy to avoid obstacles
due to acquired immunity towards already administered
viruses. (vi) The small virion size (about 30 nm in dia-
meter) of picornaviruses [11] could be an oncolytic
advantage. Fibrillar collagen has proven to inhibit rela-
tively large herpes simplex virus from reaching malignant
cells within a tumor, while nanoparticles spread more
easily [41]. (vii) Picornaviruses have a relatively fast repli-
cation cycle, ranging from five to ten hours [11]. This
could also be an advantage for viral oncolysis, since a fas-
ter replicating virus may reduce a tumor in size more
effectively than a slower replicating virus [42].
We have investigated the cytolytic capacity of E12, E15,
E17, E26 and E29 by infection of six colon cancer cell
lines derived from both primary tumors and metastases
(Table 1). To be able to address the infectious ability of
the viruses in these cell lines as explicitly as possible, no
serum was added to the medias in these viral infectivity
experiments. The results were recorded both by the abil-
ity to cause CPE (Table 2, Additional file 1), and by
proliferation efficacy (Figure 1). Highly cytolytic viruses
with an efficient propagation were also allowed to infect
spheroids (Figure 2), to investigate their ability to spread
within and destroy an artificial tumor.
When analyzing the results of the monolayer studies
(Table 2, Figure 1) CaCo-2, HT29 and SW620 were cyto-
lytically infected by all viruses, while LoVo was not cytoly-
tically infected by any of the five viruses. However, our
results suggest that E12 causes a persistent infection in
LoVo. We have not been able to find a likely cause to this
infectious disability, and it may be due to both difficulties
of viral entry as well as intracellular proliferation factors.
A cytolytic infectious cycle within the tumor cells is a
favorable characteristic of an oncolytic virus. The release
of viral progeny enables spreading to neighboring malig-
nant cells as well as metastatic sites that are distant from
primary site of administration. Interestingly, it has been
shown that the genetic difference between an EV causing
a cytolytic infection and one causing a non-cytolytic infec-
tion, in a particular cell line, may be as little as one amino
acid change [43].
The viral infections of SW480 and SW620 are interest-
ing, due to the fact that these cell lines originate from the
Figure 2 Viral infections of HT29 spheroids. Spheroids originating from 1 000 HT29 cells and grown for seven days were infected by 10
5
TCID50 of echovirus 12, 17, 26, 29 or uninfected (Control). Infections were followed for 9 days and pictures were taken at 0, 1, 5, and 9 days post
infection at 4 000 × magnification. The figure shows representative pictures of at least 14 spheroid infections per virus performed on at least
two different occasions.
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primary adenocarcinoma of the colon, while SW620 was
established from a lymph node metastasis one year later
(Table 1). The cell lines seem to respond differently to
infection of the same virus. E26 does not cause cytolysis
i nS W 4 8 0t ot h es a m ee x t e n tt h a ti td o e si nS W 6 2 0
(Table 2). The mean viral progeny of E17 in SW620 is
about 10
4 TCID50/ml, while the mean viral progeny in
SW480 is more than 10
6 TCID50/ml (Figure 1). E12 and
E29 cause CPE faster in SW480 than in SW620, and even
though E15 is not able to infect SW480, the virus causes
a cytolytic infection in SW620 (Table 2, Figure 1). This
indicates that the same viral serotype may have a differ-
ent impact when infecting cancer cells derived from the
same original cancer. Hence, there may be a “sliding ther-
apeutic window” in the progression of a cancer, where a
specific oncolytic virus has the most effective anti-cancer
effect. In this perspective, several oncolytic viral serotypes
with similar oncolytic properties may be very beneficial,
not only from an immunological point of view.
All viruses cause a cytolytic infection in T84 except E29,
which seems to cause a non-cytolytic infection (Table 2,
Figure 1). Strangely, the viral progeny titers of E12 and
E15 are lower than the initial titers in T84 (Figure 1). This
could to some extent be explained by viral progeny neu-
tralization caused by neutralizing substances released by
lysed cells, or less viable progeny production of E12 and
E15 in T84. More viral particles adsorbing to the T84 cel-
lular surface than the number of particles entering and
infecting the cells could also contribute to this effect. In
the case of E12, it is known that decay-accelerating factor
(DAF or CD55) is a cellular receptor [44,45]. This receptor
may not be enough for cellular entry, hence infection, for
DAF-binding picornaviruses [46]. It is possible that
unknown entry-receptors of E12 and E15 are not
expressed on the surface of T84 or expressed in very low
amounts. In addition, viral attachment-induced apoptosis
could contribute to the CPE observed in E12 and E15
infected T84 cells. It has been shown that high MOIs of
UV-inactivated reovirus virions can induce apoptosis in
the absence of viral replication by interacting with cell sur-
face receptors [47]. Due to the inefficient cytolytic replica-
tion of E15, this virus was excluded from further studies.
In addition to confirmation of successful lytic infections
and measurement of viral progeny following infection, an
interesting pattern emerges when comparing binding titers
of the different viruses in Figure 1. Several serotypes gen-
erate similar binding titers independent of cell line
infected. A MOI of 1 was used in the experiment and the
time required for complete CPE is not connected to initial
binding titers (Table 2). The titers of attached E12 and
E17 are relatively high, while the amount of bound E29
(and in some cases E26 and E15) are not detected in all
cell lines. This could be the result of different entry
strategies. If viruses with very low or undetected binding
titers use a highly specific attachment and entry process,
infection could be successful even at undetected initial
amount of bound virions using the TCID50 method. This
method does not tell how many infectious particles are
present in the original sample, but what dilution of virus
will generate CPE in 50% of the cells inoculated [36]. A
high titer of bound viruses indicates that relatively many
virions interact with the cell surface initially. This could be
an effect of a more virion dense attachment and entry
strategy, possibly by the use of more than one receptor.
E12, E17, E26 and E29 were further investigated in
spheroids, cells grown in three-dimensional clusters,
hence more resembling tumors than cells grown as mono-
layers. The results (Figure 2) show that E12, E17 and E26
were able to dissolve spheroids of HT29 cells grown for
seven days, starting with 1 000 cells. E29 was not able to
efficiently kill HT29 cells when grown as spheroids. These
cells were only readily infected and lysed by E29 when
grown as monolayers (Table 2, Figure 1). The viability of
E29 infected and uninfected spheroids were confirmed
after seven days by trypsination and trypan blue staining.
Trypan blue staining showed that E29 had some cytolytic
effect on the spheroids, but not enough to dissolve them.
Almost all cells from uninfected spheriods were viable
after seven days (data not shown). The viability of unin-
fected spheroids was also confirmed by letting individua-
lized spheroid cells proliferate as monolayers again (data
not shown). These results show that even though a virus
may cause cytolysis in a certain cell population when
grown as a monolayer, the same virus may not be as infec-
tious when the cells are grown in three-dimensional
clusters.
A major concern regarding all oncolytic viruses is the
existence of neutralizing antibodies from prior natural or
deliberate exposure. Employing low- or apathogenic
viruses for oncolytic purposes raises the question whether
these viruses are frequently circulating in the human
population without causing any symptoms although indu-
cing immunity. Because they are not frequently associated
with disease there are very little data published regarding
circulation of these viruses in the population. The seropre-
valence of the oncolytic candidates we present here needs
to be addressed in coming studies. However, seropreva-
lence of E1 and coxsackievirus A21, two other low-patho-
genic oncolytic enteroviruses, seems to be less than 10% in
preliminary studies [16,48]. Besides investigation of the
potential risk of preexisting neutralizing antibodies, this
study will need to be complemented with infection studies
in primary cell cultures and animal models. This would
further elucidate the oncolytic capacity of these viruses.
Knowledge of infection preferences, for example receptor
usage, of these viruses would also be a great advantage
when investigating the ability to utilize these viruses for
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lize DAF (CD55) as cellular receptor [44,45,49]. DAF is a
vital part of directing the immune system away from self-
tissue [50], and has been shown to be upregulated in
colon cancer [51,52]. In addition to in vivo studies of the
oncolytic capacity, the receptor usage of these viruses
needs to be further elucidated while bearing in mind that
enteroviruses may utilize more than one receptor [46,53].
Our study pinpoints E12, E17 and E26 as new potential
candidates for oncolytic virotherapy. It also puts focus on
a group of enteroviral serotypes that have not been exten-
sively studied before, due to the fact that they are not
causing serious diseases or financial losses to the human
population. However, seen in the light of oncolytic vir-
otherapy, these viruses may be of great interest as new
treatments in the battle against cancer.
Conclusions
In conclusion, the echoviruses 12, 17 and 26 show
potential as oncolytic agents against colon cancer. This
was found by investigating the cytolytic capacity and
replicative efficiency of E12, E15, E17, E26 and E29 in
six colon cancer cell lines as well as in artificial HT29
tumors in vitro.
Additional material
Additional file 1: Pictures of infected colon cancer cell lines. CaCo-2,
HT29, LoVo, SW480, SW620 and T84 infected with echovirus 12, 15, 17,
26, 29 (at a multiplicity of infection of 1) and uninfected (Control).
Pictures were taken at the time of complete cytopathic effect or seven
days post infection at 4 000 or 10 000 × magnification.
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